LNC’s Medical Food Stablor treats the dysfunctional metabolic processes associated with abdominal obesity

LNC (Laboratoires Nutrition et Cardiometabolisme), a research and development company specialized in the field of chronic metabolic diseases, today announces the first results of its Obeminale^® Program. Extensive clinical and real-life studies demonstrate both the safety and efficacy of the medical food Stablor^®. This novel patented product targets the underlying causes of abdominal obesity. It demonstrates a reduction in the cardiometabolic risk factors associated with obesity co-morbidities (high triglycerides, hyperglycemia and low HDL cholesterol). Consolidated results from two clinical studies and product usage in real clinical practice demonstrate that in less than six months Stablor delivers the following:

• 18% fat loss, mostly in the waist area
• 9% weight loss
• 9.5% decrease in waist circumference
• At least 5% weight loss for 67% of patients
• A high level of safety
• High patient compliance (a lower than 10% drop-out rate in clinical studies)

Stablor is composed of amino acids and micronutrients in specific proportions. It has been specifically engineered to decrease adipocyte dysfunction and adipose tissue inflammation. Additional clinical results have confirmed a significant decrease in inflammation (CRPus -11%) and a positive impact on insulin-resistance (HOMA IR -24%).
 
According to a recent report from the Journal of the American Medical Association (JAMA), the number of people with abdominal obesity (visceral fat) increased from 46.4% of the US population in 1999-2000 to 54.2% in 2011-2012.
 
Stablor is now ready for market and can be prescribed to any individual with abdominal obesity and co-morbidities. It has already been prescribed to 5,000 individuals. Stablor has the potential to strengthen the portfolio of any major business with a cardiometabolic focus. A rapid launch in key markets will target up to 700 million people. “We welcome enquiries from potential partners. This can accelerate the commercialization of Stablor, making it available to a large number of users” said Jean-Luc Treillou, CEO at LNC.
 
The LNC’s approach to the effective management of metabolic dysfunction also includes a patient-centric and behavioral approach called the Chronic Patient Initiative (CPI), a patient support program. Abdominally obese people have multiple health challenges (nutritional imbalances, inadequate lifestyle etc). It is critical to address these issues simultaneously with a holistic approach to achieve lasting, long-term success.
 
The final results of the Obeminale program, to be published in early 2015, will include microbiota and adipose tissue details.
 
“We are convinced that LNC’s approach offers an effective patient management program in the field of cardiometabolic diseases,” said Claude Vincent, president at LNC. “Stablor is our lead product. However, as an R&D company we also have four additional programs under development: medical foods targeting metabolic disorders related to subfertility, bariatric surgery, pre-diabetes and Non-Alcoholic SteatoHepatitis (NASH) – with successive market launches planned over the next four years.”